

Terms & Conditions:

1. The competition is open to all licensed health care professionals / Pharmacists in South Africa with a valid South African ID document, except the employees of iNova Pharmaceuticals and their immediate families, advertising and promotion agencies and associated companies.
2. Competition 1 will run from 1 April to 30 June 2024. Competition 2 will run from 1st May to 30th June 2024.
3. To enter, the healthcare professional must complete the question and hand the competition form to the rep.
4. The winners will be notified by an iNova Pharmaceuticals representative.
5. Competition 1 is one of 75 pairs of branded tekkies valued at R250 each incl. VAT per competition. Competition 2 is one of 75 pairs of branded tekkies valued at R250 each incl. VAT per competition.
6. The governing law to apply in respect to this promotion is that of the Republic of South Africa.
7. Main prize guarantee legalities to be provided by supplier. iNova cannot guarantee that the images of the prize will be the exact models delivered to prize winners.
8. iNova collects personal information in order to conduct the competition and may, for this purpose, disclose such information to third parties, including but not limited to, prize suppliers and as required, to South African regulatory authorities. Entry is conditional upon providing this information. By entering this competition, entrants' consent to the collection and use of personal information as set forth herein.
9. All entries become the property of iNova. iNova will not use the content of entries for the purpose of future promotions.
10. Eligible entrants' consent to iNova using their name, likeness and/or image in the event they are a winner (including photographs, films) in any media for an unlimited period, without any remuneration.

11. We respect your privacy. Any personal information you have provided will be collected and used for the primary purpose set out above. You can view details on how we manage personal information in our privacy policy at www.inovapharma.com/privacy.

12. The competition is not dependent on the recommendation prescription/purchase of the product.

References: 1. Duro-Tuss Linctus professional information, August 2021. 2. Cough treatment. Specialist Forum 2017;17(6):28-30. 3. Sears MR, Lotvall J. Past, present and future— β 2-adrenoceptor agonists in asthma management. Resp Med 2005;99:152–170

Scheduling status: S2 Proprietary name (and dosage form): DURO-TUSS® Linctus liquid.
Composition: Each 5 ml liquid contains Salbutamol sulphate 2.41 mg; Bromhexine hydrochloride 4 mg. Registration number: A39/10.1/0390.

Name and business address of applicant: iNova Pharmaceuticals (Pty) Ltd. Co. Reg. No. 1952/001640/07.15e Riley Road, Bedfordview. Tel: 011 087 0000. www.inovapharma.co.za.

For full prescribing information, refer to the professional information as approved by the SAHPRA (South African Health Products Regulatory Authority), available at www.inovapharma.co.za. Further information is available on request from iNova Pharmaceuticals. 23121L. IN4558/23.